公司回答表示：您好，非常感谢您对公司研发的关注，产品一致性评价过程中的审评发补是国家药监局 审评中心正常审评环节。公司将按照法律法规进行信息披露。责任编辑：栎树 金融界7月31日消息，有投资者在互动平台向红日药业提问：贵公司的注射用胸腺法新一致性评价离开 审评队列已经7天了，还没有获批，大概率又是发补了。回顾贵公司近两年的一致性评价，几乎没有一 次性顺利通过的品种。请问贵公司难道不反思自己的研发能力已经弱到极点了嘛？如何在一个以创新致 胜的医药环境中生存发展呢？ ...

Core Viewpoint - The concept of generic drug consistency evaluation has seen a rise of 2.73%, ranking fifth among concept sectors, with significant inflows of capital into various stocks within this sector [1][2]. Group 1: Market Performance - As of July 1, the generic drug consistency evaluation concept experienced a 2.73% increase, with 120 stocks rising, including top performers like Fengyuan Pharmaceutical, Guizhou Bailing, and Anglikang, which hit the daily limit [1]. - The leading gainers in this sector included Yuekang Pharmaceutical (up 15.55%), Yipinhong (up 14.72%), and Hongri Pharmaceutical (up 8.13%) [1][2]. - Conversely, the stocks with the largest declines were Yiming Pharmaceutical, Yongtai Technology, and *ST Suwu, which fell by 2.16%, 1.71%, and 0.79% respectively [1]. Group 2: Capital Inflows - The generic drug consistency evaluation sector attracted a net inflow of 829 million yuan, with 74 stocks receiving capital inflows, and 13 stocks seeing over 50 million yuan in net inflows [2]. - The stock with the highest net inflow was Yipinhong, which saw 168 million yuan, followed by Guizhou Bailing and Huahai Pharmaceutical with net inflows of 158 million yuan and 135 million yuan respectively [2][3]. - The top three stocks by net inflow ratio were Fengyuan Pharmaceutical (24.78%), Guizhou Bailing (17.80%), and Huahai Pharmaceutical (14.87%) [3]. Group 3: Stock Performance Metrics - Yipinhong had a daily increase of 14.72% with a turnover rate of 5.65% and a net capital flow of approximately 168 million yuan [3]. - Guizhou Bailing increased by 10.04% with a turnover rate of 13.11% and a net capital flow of about 158 million yuan [3]. - Huahai Pharmaceutical rose by 5.74% with a turnover rate of 3.26% and a net capital flow of around 135 million yuan [3].

Core Viewpoint - The article highlights significant policy support for the innovative drug sector in China, which is expected to drive growth and investment opportunities in the industry [2][6][10]. Policy Support - The National Healthcare Security Administration and the National Health Commission issued measures to support the high-quality development of innovative drugs, including 16 specific initiatives across five areas [2][6]. - The measures include utilizing healthcare data for innovative drug research and encouraging commercial health insurance to expand investment in innovative drugs [6][7]. Market Reaction - Following the announcement of the supportive policies, innovative drug stocks surged, with companies like Sali Medical and Guizhou BaiLing hitting the daily limit, and others like Shuyitai and Hotgen Biotech seeing significant gains [3][5]. Future Outlook - Analysts predict that 2025 will be a pivotal year for domestic innovative drug companies to expand internationally, driven by technological innovation and market growth [4][12]. - The innovative drug market is expected to continue expanding, with a notable increase in overseas licensing deals and a shift from capital-driven growth to profit-driven growth [11][12]. Investment Opportunities - Investment strategies should focus on potential companies that may expand internationally, particularly in areas such as next-generation immunotherapy, antibody-drug conjugates (ADC), and breakthroughs in chronic disease treatments [11][12].

受托管理事务报告 （2024 年度） 2021 年面向专业投资者公开发行公司债券 （第一期） 天津红日药业股份有限公司 债券受托管理人 天风证券股份有限公司 2025 年 6 月 本报告不构成对投资者进行或不进行某项行为的推荐意见，投资 者应对相关事宜做出独立判断，而不应将本报告中的任何内容据以作 为天风证券所作的承诺或声明。在任何情况下，投资者依据本报告所 进行的任何作为或不作为，天风证券不承担任何责任。 3 第一章 债券概况 一、 债券名称：天津红日药业股份有限公司 2021 年面向专业投 资者公开发行公司债券（第一期）。 二、 债券简称及代码：21 红日 01，149604.SZ。 | 重要声明 3 | | | --- | --- | | 第一章 | 债券概况 4 | | 第二章 | 受托管理人履行职责情况 6 | | 第三章 | 发行人的经营与财务状况 7 | | 第四章 | 发行人募集资金使用及专项账户运作情况与核查情况 13 | | 第五章 | 发行人信息披露义务履行的核查情况 14 | | 第六章 | 内外部增信机制、偿债保障措施的有效性分析，重大变化 | | 及发行人偿债保障措施的执行情况 | ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-038 特别提示： 1、天津红日药业股份有限公司（以下简称"公司"）2024年年度权益分配 方案已获2025年5月20日召开的2024年度股东大会审议通过，股东大会决议公告 刊登于2025年5月20日中国证监会创业板指定信息披露网站。 2、本次权益分派实施后除权除息参考价=除权除息日前一交易日收盘价-按 公司总股本折算的每股现金分红=除权除息日前一交易日收盘价-0.3000000元/ 股。现将权益分派事宜公告如下： 一、股东大会审议通过的权益分派方案情况 1、公司2024年度股东大会审议通过《关于2024年度利润分配预案的议案》， 权益分派方案为：以现有总股本3,004,154,837股为基数，按每10股派发现金股 利人民币0.30元（含税），共计90,124,645.11元。以上方案实施后，剩余未分 配利润4,653,521,466.58元结转以后年度分配。在利润分配预案披露后至权益分 派实施股权登记日之间公司股本发生变动的，将按照上述分配比例不变的原则进 行调整。 2、自上述分配方案披露实施期间，公司股本总额未发生变 ...

Market Overview - On May 23, the A-share market showed strong performance before noon but retreated in the afternoon, with the Shanghai Composite Index down 0.94% to 3348.37 points, the Shenzhen Component Index down 0.85% to 10132.41 points, and the ChiNext Index down 1.18% to 2021.50 points [2] - The total market turnover was 118.26 billion yuan, an increase of 42.9 billion yuan compared to the previous trading day [2] - Leading sectors included pharmaceuticals, automotive supply chains, and controllable nuclear fusion, while previously popular micro-cap stocks continued to adjust [2] Pharmaceutical Sector - The pharmaceutical sector experienced a strong surge, with leading innovative drug company Heng Rui Pharmaceutical listing on the Hong Kong Stock Exchange and seeing its stock price rise over 25%, boosting the entire innovative drug industry chain [3] - A-share pharmaceutical stocks rose against the trend, with companies like Hai Chen Pharmaceutical and Zhong Sheng Pharmaceutical hitting the daily limit, while Hua Sen Pharmaceutical and Cheng Da Pharmaceutical also saw gains [3] - Multiple innovative drug companies announced they would showcase their research results at the 2025 American Society of Clinical Oncology (ASCO) annual meeting from May 30 to June 3 [3] - The market's expectations for domestic innovative drugs going global were heightened following the news of a dual-antibody new drug licensing collaboration between Sanofi and Pfizer [3] - According to NextPharma, Chinese pharmaceutical companies completed 41 overseas licensing transactions in Q1 2025, totaling 36.9 billion USD, nearing the total for the entire year of 2023 [3] - From 2015 to 2024, China ranked first globally in the cumulative number of original innovative drugs developed [4] - Zhonghang Securities noted that the innovative drug industry is undergoing profound changes, with companies enhancing their core advantages and transitioning from followers to significant players in international competition [3] Micro-Cap Stocks - Micro-cap stocks initially performed well but began to adjust from mid-week, with high-profile stocks like Nanjing Port and Langsha experiencing significant fluctuations [5] - Wangzi New Materials gained attention from active market funds, achieving a limit-up on May 23 and recording five consecutive trading days of gains, effectively doubling in value [5] - According to Founder Securities, the dominance of micro-cap stocks has been a notable feature of the A-share market this year, with strong mean reversion properties observed in small-cap styles [5] - The outlook for the market suggests that the trend favoring micro-cap stocks may continue, supported by factors such as a stable capital market, ongoing economic transformation, and sustained liquidity [5]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-037 天津红日药业股份有限公司 关于公司控股子公司完成注销登记的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 近日，公司收到天以红日发送的天津经济技术开发区市场监督管理局出具的 《注销核准通知书》，天以红日已办理完成注销登记手续。 三、注销参股公司对公司的影响 本次注销完成后，天以红日不再纳入公司合并报表范围，对公司整体业务发 展和财务状况不存在实质性影响，也不会对公司整体业务发展和盈利水平产生重 大不利影响，不存在损害公司权益和全体股东特别是中小股东的合法权益的情形。 1 天津红日药业股份有限公司 一、控股子公司情况概述 2010 年 10 月 25 日，天津红日药业股份有限公司（以下简称"公司"）召开 了第四届董事会第七次会议，审议通过了《投资设立天以红日医药科技发展(天 津)有限公司的议案》。公司计划使用自有资金 1,600 万元人民币与英飞尼迪资本 管理有限公司、天津滨海天使创业投资有限公司共同投资设立天以红日医药科技 发展(天津)有限公司（以下简称"天 ...

Group 1 - The company held its first meeting of the ninth supervisory board on May 21, 2025, where all members confirmed the meeting's compliance with relevant laws and regulations [2][3] - The supervisory board elected Ms. Ye Shangshu as the chairperson of the ninth supervisory board for a term of three years [3][4] - The election of the ninth supervisory board members was approved at the annual shareholders' meeting held on May 20, 2025, with Ms. Ye Shangshu and Mr. Li Jun elected as non-employee representatives [3] Group 2 - Ms. Ye Shangshu, born in September 1986, holds a bachelor's degree and currently serves as the company's supervisor and chairperson of the supervisory board [4] - Ms. Ye does not hold any shares in the company and has no related relationships with major shareholders or other board members [4]

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-034 天津红日药业股份有限公司（以下简称"公司"）第九届监事会第一次会议 于 2025 年 05 月 21 日在天津市武清开发区创业总部基地 B01 号楼公司会议室以 现场加通讯表决方式召开,会议通知于 2025 年 05 月 17 日以邮件、电话的方式发 出。会议应参加监事 3 人，实际参加会议的监事 3 人（其中以通讯表决方式出席 会议的监事为 2 人）。本次会议以通讯表决的监事分别为：监事叶尚书女士、监 事李俊先生。本次监事会由半数以上监事共同推举叶尚书女士召集并主持，公司 部分高级管理人员列席了会议。本次会议召开符合《公司法》等相关法律法规和 《公司章程》《公司监事会议事规则》的有关规定。 会议由公司监事叶尚书女士主持，参会监事投票表决通过如下议案： 审议通过《关于选举叶尚书女士为公司第九届监事会主席的议案》。 公司于 2025 年 05 月 20 日召开了 2024 年度股东大会，审议通过了《关于监 事会换届选举暨选举第九届监事会非职工代表监事的议案》，同意选举叶尚书女 士、李俊先生为第九届监事会非职工代表监 ...

天津红日药业股份有限公司 证券代码：300026 证券简称：红日药业 公告编号：2025-035 天津红日药业股份有限公司 关于选举公司第九届董事会董事长、副董事长、专门委员 会委员及聘任公司高级管理人员、证券事务代表的公告 本公司及董事会全体成员保证信息披露的内容真实、准确、完整，没有虚假记载、误 导性陈述或重大遗漏。 天津红日药业股份有限公司（以下简称"公司"）于 2025 年 05 月 21 日召开 了第九届董事会第一次会议，审议通过了《关于选举公司第九届董事会审计委员 会委员的议案》《关于选举公司第九届董事会提名委员会委员的议案》《关于选举 公司第九届董事会战略委员会委员的议案》《关于选举公司第九届董事会薪酬与 考核委员会委员的议案》《关于选举公司第九届董事会董事长的议案》《关于选举 公司第九届董事会副董事长的议案》《关于聘任公司高级管理人员的议案》及《关 于聘任公司证券事务代表的议案》，选举产生了公司第九届董事会董事长、副董 事长、各专门委员会委员及聘任公司高级管理人员、证券事务代表。现将相关情 况公告如下： 1 天津红日药业股份有限公司 司第九届董事会第一次会议审议，董事会同意选举以下董事为公司第 ...